Literature DB >> 2642948

A method for removing interleukin-1- and tumor necrosis factor-inducing substances from bacterial cultures by ultrafiltration with polysulfone.

R Schindler1, C A Dinarello.   

Abstract

The ability of human mononuclear cells (MNC) to produce cytokines is a highly sensitive and biologically relevant test system for the presence of microbial products. The safety of parenteral fluids is presently determined by gelation of the limulus amebocyte lysate (LAL) to endotoxin. In the present study, crude bacterial culture supernatants from Escherichia coli were subjected to ultrafiltration using polysulfone and the ultrafiltrates were tested for their ability to stimulate human MNC. Total interleukin-1 (IL-1) and tumor necrosis factor (TNF) produced by MNC were measured by radioimmunoassay. Endotoxin-like substances in E. coli cultures are rejected by a factor of at least 100,000. Rejection takes place by molecular size exclusion and by absorption. The sensitivity of the LAL and MNC cytokine production were comparable. These studies demonstrate a wide margin of safety for the production of parenteral fluids using ultrafiltration for endotoxin-containing materials.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642948     DOI: 10.1016/0022-1759(89)90199-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  11 in total

Review 1.  Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis.

Authors:  B Kirkham
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

2.  Gram-negative bacterial lipopolysaccharide retention by a positively charged new-generation filter.

Authors:  Ilaria Bononi; Veronica Balatti; Soccorso Gaeta; Mauro Tognon
Journal:  Appl Environ Microbiol       Date:  2008-08-22       Impact factor: 4.792

3.  Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells.

Authors:  J P Drenth; J Göertz; M R Daha; J W van der Meer
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

4.  Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.

Authors:  S Endres; H J Fülle; B Sinha; D Stoll; C A Dinarello; R Gerzer; P C Weber
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

5.  Live Borrelia burgdorferi preferentially activate interleukin-1 beta gene expression and protein synthesis over the interleukin-1 receptor antagonist.

Authors:  L C Miller; S Isa; E Vannier; K Georgilis; A C Steere; C A Dinarello
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells.

Authors:  J M Molina; D T Scadden; C Amirault; A Woon; E Vannier; C A Dinarello; J E Groopman
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity.

Authors:  J Semmler; U Gebert; T Eisenhut; J Moeller; M M Schönharting; A Alléra; S Endres
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

8.  Ciliary neurotrophic factor is an endogenous pyrogen.

Authors:  L Shapiro; X X Zhang; R G Rupp; S M Wolff; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  Histamine inhibits the production of interleukin-12 through interaction with H2 receptors.

Authors:  T C van der Pouw Kraan; A Snijders; L C Boeije; E R de Groot; A E Alewijnse; R Leurs; L A Aarden
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

10.  Osmotic regulation of cytokine synthesis in vitro.

Authors:  L Shapiro; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.